AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT00855959
- Locations
- 🇯🇵
Research Site, Tachikawa, Tokyo, Japan
🇯🇵Research City, Hino, Tokyo, Japan
Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 182
- Registration Number
- NCT00855166
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Bleeding Time Study With AZD6482, Clopidogrel and ASA
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2009-08-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00853450
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2009-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00853983
- Locations
- 🇬🇧
Research Site, Alderley Park, Cheshire, United Kingdom
Seroquel XR in Adults With Schizophrenia
Phase 3
Terminated
- Conditions
- Schizophrenia
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00852631
- Locations
- 🇹🇭
Research Site, Songkla, Thailand
ATAC - Arimidex, Tamoxifen Alone or in Combination
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: Anastozole (Arimidex)Drug: Anastozole (Arimidex) placebo
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9358
- Registration Number
- NCT00849030
Management of Cardiovascular Risk Factors
Completed
- Conditions
- Cardiovascular Risk FactorsCardiovascular Diseases
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2010-11-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1492
- Registration Number
- NCT00848380
- Locations
- 🇨🇭
Research Site, Zurich, ZH, Switzerland
AZD9164 Single Ascending Dose Study in Healthy Male Subjects
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2009-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00847249
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 101
- Registration Number
- NCT00846976
- Locations
- 🇺🇸
Research Site, New York, New York, United States
Bioequivalence Study in Healthy Subjects
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00844324
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom